AASLD Issues Its First Expert Opinion Document, and It Is on Liver Biopsy. It Is Not a Guideline.
The society's first Expert Practice Opinion updates its 2009 biopsy guidance, adds endoscopic ultrasound-guided biopsy and sets specimens of more than 1.5 cm. It rests on expert consensus, not GRADE, and sets no INR or platelet cutoff.
The American Association for the Study of Liver Diseases (AASLD) announced on Oct. 15 the publication of its first Expert-Based Practice Opinion, or EXPO, and the subject is liver biopsy. The document in Hepatology, by Elizabeth C. Verna, Douglas G. Adler, Matthew R. Kappus, Elizabeth B. Rand, Elliot B. Tapper and Don C. Rockey, was posted online Oct. 7. It updates the society's 2009 liver biopsy guidance to account for noninvasive liver disease assessment and the arrival of endoscopic ultrasound-guided liver biopsy (EUS-LB).
How it differs from a guideline
AASLD describes the EXPO as a new kind of resource for areas where evidence is limited, emerging or changing too fast for a formal GRADE-based guideline. The paper states that no systematic review or GRADE methodology was used. A writing group appointed by the AASLD Practice Guidelines Committee did a targeted literature review and wrote opinion statements all members agreed on. When you cite it, cite it as expert consensus. A commentary from the committee (doi:10.1097/HEP.0000000000001824) accompanies it.
When to biopsy
The document names three indications: establishing a diagnosis, staging inflammation or fibrosis, and informing management. It says biopsy should be considered for unexplained abnormal liver tests, when noninvasive fibrosis testing is uncertain or discordant, and when histology will change a management decision. Its examples include a high FIB-4 with a nodular liver but low liver stiffness, autoimmune hepatitis when stopping immunosuppression is under consideration, abnormal tests after liver transplant and a payer that requires biopsy-confirmed fibrosis staging before therapy.
The authors are direct about the limits. A specimen is about 1/50,000th of the liver, interobserver concordance for fibrosis staging is 78 percent even among expert pathologists, and in 51 patients with metabolic dysfunction-associated steatotic liver disease sampled from both lobes, 35 percent had F3 fibrosis on one side and F0 or F1 on the other. In unexplained liver test elevations, a histologic diagnosis is made in 74 to 94 percent of cases, but histology is normal in up to 15 percent.
For the physician who orders the biopsy, the useful change is a shared standard: a clear clinical question on the requisition and a specimen big enough to answer it.
Technique, bleeding and adequacy
Percutaneous, transjugular and EUS-guided approaches are all covered, with choice depending on local expertise, anatomy, ascites, coagulopathy, concurrent procedures such as portal pressure measurement and patient preference. In adults, imaging localization should be used immediately before or during percutaneous biopsy. Major bleeding after percutaneous biopsy occurs in about 0.3 to 0.6 percent of patients and death in fewer than 0.1 percent.
The authors found no evidence for a specific INR threshold and called platelet transfusion cutoffs unclear. They suggest individualizing decisions with a hematologist for severe coagulation or platelet abnormalities and say a transjugular approach is usually preferred for those patients and for those on anticoagulant or antiplatelet therapy. Routine right lateral decubitus positioning after percutaneous biopsy is not supported by evidence and may add discomfort.
On adequacy, the specimen should be longer than 1.5 cm for all biopsy types, the pathology report should state whether it contains more than 11 portal tracts, and the minimum needle is 19-gauge for transjugular and EUS-guided biopsy, with 16-gauge or larger preferred percutaneously.
What it means in clinic
Most physicians who order liver biopsies do not perform them, and the EXPO's practical asks fall on the referrer as much as the proceduralist. Put the indication and a specific clinical question on the requisition, since the authors say that is what makes the pathologist's read useful. When noninvasive fibrosis results disagree, ask whether histology would change management, because that is the document's test for proceeding. And when a result is ambiguous or will drive a high-stakes decision such as transplant, the authors recommend expert pathology review, a point our piece on the second look in diagnosis also makes.
Reported, fact-checked and edited by The Script Pad's editorial staff.
This article is for professional education and does not replace clinical judgment. Treatment decisions should be based on the individual patient and current guidelines.
